Company: LGNZZ
Filing Date: 2025-08-11
Form Type: 8-K
Source: 0001193125-25-177452
Chunk: 1

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-08-11
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01      Other Events.  

On August 11, 2025, the Company issued a press release announcing the proposed offering of $400 million aggregate principal amount of convertible senior notes due 2030 (the “ Notes”) in a private placement (the “ Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “ Securities Act”). The Company also announced its intent to grant the initial purchasers of the Notes an option to purchase, during a13-dayperiod beginning on, and including, the first date on which the Notes are issued, up to an additional $60.0 million aggregate principal amount of Notes. A copy of the press release announcing the Offering is attached hereto as Exhibit 99.1 and incorporated herein by reference.

This Current Report on Form8-Kis neither an offer to sell nor a solicitation of an offer to buy any securities, nor shall it constitute an offer to sell, solicitation of an offer to buy or sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offers of the securities would be made only by means of a confidential offering memorandum. These securities have not been registered under the Securities Act or any state securities laws and, unless so registered, may not be offered or sold in the United States or to U. S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state laws.